Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Controlled Trial to Deprescribe for Older Patients With Polypharmacy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hospitalized at Vanderbilt University Medical Center~* Medicare-eligible~* Discharged from VUMC to a post acute care facility~* Has polypharmacy as defined by \> 5 medications~* Able to self-consent or has a proxy (surrogate)~* Speaks English (due to interview-based assessments)~* Primary home residence within one of 9 surrounding counties (due to home visit during follow-up phase)~Exclusion Criteria:~* Resides in long-term care~* Is currently on hospice or otherwise has a limited life expectancy (\< 6 months).~* Enrolled in a clinical drug trial~* Has Stage IV Cancer Diagnosis~* Incarcerated or homeless~* Unable to self-consent and does not have a surrogate

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Shed-Meds: A Patient-Centered Deprescribing Intervention (Type: EXPERIMENTAL): Participants assigned to the intervention group will receive a clinical review of their prescribed medications by a research clinician (Pharmacist, Physician, and/or Nurse Practitioner) followed by a patient interview to assess their willingness to discontinue or reduce some of their medicines based on the clinical recommendations of the team. Hospital and out-patient providers also will be part of the deprescribing decision process. Deprescribing actions will be initiated in the hospital prior to discharge and continue through the skilled nursing facility stay.
- Control Group (Type: NO_INTERVENTION): Participants assigned to the control group will receive usual care as it is normally provided by the hospital and skilled nursing facility treatment teams. Research staff will monitor their prescribed medications in both care settings but not make any recommendations or changes, unless a safety issue is identified.

Based on this trial design, predict the completion outcome and termination type (if applicable).